Mutation News and Research

RSS

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

In preliminary experiments with mice and lab-grown cells, Johns Hopkins Kimmel Cancer Center scientists have found that a protein-signaling process accelerates the work of the gene most frequently mutated in a common form of adult leukemia and is likely necessary to bring about the full-blown disease.

11 Jun 2015

Scientists find new way of classifying brain cancers

Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.

11 Jun 2015

New approach to classifying brain tumors could lead to significant improvements in diagnosis, treatment

A Case Comprehensive Cancer Center brain surgeon and neurosurgery professor is among the primary authors of a new approach to classifying tumors that could lead to significant improvements in their diagnosis and treatment. The research and recommendations appear online June 10 in The New England Journal of Medicine.

11 Jun 2015

Two fragile X proteins play crucial role in proper development of neurons

Fragile X syndrome is the most common inherited intellectual disability and the greatest single genetic contributor to autism. Unlocking the mechanisms behind fragile X could make important revelations about the brain.

11 Jun 2015

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism.

11 Jun 2015

Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

A previously unknown link between the immune system and the death of motor neurons in Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been discovered by scientists at the CHUM Research Centre and the University of Montreal. The finding paves the way to a whole new approach for finding a drug that can cure or at least slow the progression of such neurodegenerative diseases as ALS, Alzheimer's, Parkinson's and Huntington's diseases.

10 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Children undergoing deep brain stimulation for generalized dystonia experience better outcomes

Children and adolescents who received deep brain stimulation for generalized dystonia maintained significant symptom relief for up to eight years, according to a study presented today at the 12th World Congress of the International Neuromodulation Society.

10 Jun 2015

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.

10 Jun 2015

Manchester first to implement Congenica's Sapientia technology to provide fast, accurate diagnosis for genetic diseases

10,000 new patients a year are treated by the Manchester Centre for Genomic Medicine (MCGM) for a range of rare diseases including cancers, developmental disorders and disabilities including hearing and vision loss - diagnosis can be time-consuming and invasive.

10 Jun 2015

ITbM researchers find new molecules that change circadian rhythm in mammals

A team of chemists and biologists at the Institute of Transformative Bio-Molecules, Nagoya University have succeeded in finding new molecules that change the circadian rhythm in mammals by applying synthetic chemistry methods, which makes use of highly selective metal catalysts.

10 Jun 2015

Study finds increased rates of autism among the children of teen moms

The largest-ever multinational study of parental age and autism risk, funded by Autism Speaks, found increased autism rates among the children of teen moms and among children whose parents have relatively large gaps between their ages. The study also confirmed that older parents are at higher risk of having children with autism. The analysis included more than 5.7 million children in five countries.

10 Jun 2015

Whole genome sequencing can help implement rapid-response infection control protocols

Whole genome sequencing can quickly isolate the specific strain of bacteria causing an outbreak, identify the source of contamination, and enable rapid infection prevention to stop the spread of infection, according to a study published today.

9 Jun 2015

NGS mutational testing can help detect patients with Barrett's esophagus

Barrett's esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus. Although periodic surveillance for cancer is recommended for BE patients, these examinations may fail to identify pre-cancerous dysplasia and early cancers.

9 Jun 2015

Electroporation technique brings higher efficiency, higher throughput genome engineering in animal models

Jackson Laboratory researchers have shown that using an electric current to deliver the CRISPR/Cas9 system, in order to engineer genetic changes in laboratory mice, is highly efficient and significantly improves the system's throughput.

9 Jun 2015

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Quality control is important - this is not only applicable to industrial production but also true for all life processes. However, whereas an enterprise can start a large-scale recall in case of any doubt, defects in the quality control systems of cells are often fatal.

9 Jun 2015

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).

9 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

Mutation News and Research

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Scientists find new way of classifying brain cancers

New approach to classifying brain tumors could lead to significant improvements in diagnosis, treatment

Two fragile X proteins play crucial role in proper development of neurons

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Children undergoing deep brain stimulation for generalized dystonia experience better outcomes

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

Manchester first to implement Congenica's Sapientia technology to provide fast, accurate diagnosis for genetic diseases

ITbM researchers find new molecules that change circadian rhythm in mammals

Study finds increased rates of autism among the children of teen moms

Whole genome sequencing can help implement rapid-response infection control protocols

NGS mutational testing can help detect patients with Barrett's esophagus

Electroporation technique brings higher efficiency, higher throughput genome engineering in animal models

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News